Affinity Asset Advisors’s Repare Therapeutics RPTX Stock Holding History

Affinity Asset Advisors’s Portfolio RPTX Stock Details RPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-200,000	Closed	-$352K	–	117
2025 Q3	$352K	Hold	200,000	–	–	0.03%	91
2025 Q2	$278K	Hold	200,000	–	–	0.04%	82
2025 Q1	$197K	Buy	200,000 +100,000	+100%	+$121K	0.02%	92
2024 Q4	$131K	Sell	100,000 -73,351	-42%	-$218K	0.02%	79
2024 Q3	$596K	Buy	+173,351	New	+$571K	0.08%	76
2022 Q3	–	Sell	-321,200	Closed	-$4.49M	–	78
2022 Q2	$4.49M	Sell	321,200 -147,705	-31%	-$1.74M	1.89%	20
2022 Q1	$6.68M	Buy	468,905 +197,127	+73%	+$2.92M	1.07%	17
2021 Q4	$5.73M	Buy	+271,778	New	+$6.4M	2.08%	19

Other funds holding RPTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Affinity Asset Advisors's RPTX Position: Q4 2025 in Review

Affinity Asset Advisors sold out of Repare Therapeutics (RPTX) in Q4 2025, closing a stake of 200,000 shares — an estimated $352K sold.

Affinity Asset Advisors first reported a position in RPTX in Q4 2021 and held it in 8 quarters. The position peaked at $6.68M in Q1 2022. 46 funds tracked by Wall St. Rank hold RPTX as of Q4 2025.

Affinity Asset Advisors reported no remaining Repare Therapeutics position as of Q4 2025 after selling out during the quarter.
Affinity Asset Advisors sold 200,000 Repare Therapeutics shares in Q4 2025, an estimated $352K.
Affinity Asset Advisors first reported a position in Repare Therapeutics in Q4 2021 and held it in 8 quarters.
Affinity Asset Advisors's Repare Therapeutics position peaked at $6.68M in Q1 2022.
46 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.